Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise cured by means ...
Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.
The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...
US companies Incyte and Syndax Pharmaceuticals today announced results from the pivotal Phase II AGAVE-201 trial of Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...